Benefits: plant bioengineering and disease control in humans:

------------------------------------------------------------------------

In the not-so-distant future, kids may love the banana for more than its nutrition or sweetness. Researchers are working to develop a banana that is an "edible vaccine" to fend off hepatitis, one of the world's most widespread and devastating diseases.

What's the banana's appeal? "It's one of the infants' first foods and can be eaten raw (cooking renders the vaccine ineffective), and it's widely available in the developing world," noted Charles J. Arntzen, Ph.D., of Texas A&M's Institute of Biosciences and Technology, who has been working on oral vaccine research for years. He emphasizes that an oral vaccine could save the lives of millions of children, especially in developing countries. For example, an estimated 300 million people carry the hepatitis virus, and about one-third will die from its effects this year.

Because most vaccines are made of proteins that are destroyed in the human gut, they must be delivered directly into the bloodstream through injection. But traditional vaccinations require needles, sterilization equipment and refrigeration, which are prohibitively expensive in many countries if available at all. Arntzen estimates the altered banana could deliver the vaccine at 2 cents a dose versus $125.

To go from food to medicine, plants are injected with minute quantities of the virus' protein coat, which contains DNA. The protein fragments attach to the plant cells' chromosomes and enter the plants genetic code. The plants then reproduce the viral proteins, which act as antigens and provoke an immune response in the body when the plant is eaten. The first success came in 1992 when mice developed antibodies against hepatitis B after being injected with proteins developed in tobacco plants.

The prescription fruit idea recently got a shot in the arm when Arntzen reported in the May 6 issue of Science that mice had developed antibodies against an infectious bacterium after being fed genetically altered, raw potato tubers. And in the May 1995 issue of Bio/Technology, he announced the first successful introduction of foreign proteins into a banana.

But before the world's kids can face vaccination without wincing, researchers must find a way to get enough proteins into the body to produce the disease-fighting immune response. Although some types of proteins degrade in the human digestive tract, others are "encapsulated" within the plant cells, which makes it easier for them to survive the trip through the stomach and into the small intestine where they can be absorbed into the bloodstream.

"The trick is getting the cells of the plant to do something they aren't used to doing - producing the viral proteins - and to produce enough of the protein to provoke an immune response," said Arntzen. He estimates it will be five to ten years before the banana vaccine can be tested in humans.

Delicious Vaccines Axis Genetics, plc by William A. Wells (Posted April 30, 1999 · Issue 53)

Abstract

If the developing world could grow vaccines, they could afford them. But will edible vaccines work?

The vaccine industry is turning babies into pincushions. Although some vaccines are combined, there is still more than one injection per baby, and plenty of screaming in pediatric offices. How soothing, then, to think of the injection being replaced by toothless munching on some mashed banana.

For developing countries, an edible vaccine could stop far more than a baby's screaming. If the transgenic plant containing the vaccinating material can be grown on site, vaccination logistics could be simplified, and costs reduced.

Several large companies such as Dow and DuPont are moving into this area, but it is a small company named Axis Genetics, plc (Cambridge, United Kingdom) that is leading the way. The next few years will be crucial for Axis, as it moves beyond the promising early science, and into the real world of vaccine production.

First the Virus

The quickest way to make lots of a foreign protein in a plant is to infect the plant with a virus. Axis started with the cowpea (known in the United States as the black-eyed pea) and its fast-growing virus CPMV (cowpea mosaic virus). The coat of CPMV is derived from the splice and cleavage products of a single gene, and up to 38 amino acids can be inserted into a loop of the coat protein with no adverse effects on coat assembly. Axis is using this system, dubbed Epicoat, for vaccines against Pseudomonas aeruginosa, Staphylococcus aureus, and cancer (the latter directed against a mucin expressed on breast cancer cells).

Epicoat is an alternative to peptide vaccines, which were first proposed in the 1980s and have struggled to establish themselves ever since. Axis CEO Iain Cubitt sees the lack of conformational stability in these peptides as a crucial flaw, and says that the Axis technology solves this by putting the peptide in a structured loop.

Epicoat is a purified injectable, but purified inhalant and non-purified edible forms may follow. Inhaled or ingested vaccines encounter the sites that are used by most infecting pathogens, and these vaccines should induce more effective immunity - mucosal immunity and secretory IgA antibodies, in addition to serum antibodies. This approach is not practical for peptide vaccines made by chemical synthesis because of the large amounts of material necessary, but the quantity is reasonable for a plant-based vaccine.

But with Epicoat the worst defect of peptide vaccines remains. "Epicoat can make a lot of material but you can only display a single epitope," says Hugh Mason of the Boyce Thompson Institute for Plant Research, Inc. (BTI; Ithaca, New York). "There is not a lot of data so far that single epitope vaccines will be very useful." With single epitope vaccines, it takes but a single mutation for the infectious agent to avoid the vaccine-induced immunity. This has led some investigators to string together several peptides in the same insertion site, an approach that is the subject of an Axis patent application. "It is likely that several peptides represents a more realistic approach than a single peptide," says Harry Greenberg of Stanford University (Palo Alto, California), who helped develop the newly released rotavirus vaccine.

I Say Potato, Dan says Potatoe

If the limiting factor is the amount of protein sequence that can be inserted in the virus, why not insert the whole protein into the plant? This thought, or something similar to it, occurred to Roy Curtiss and Guy Cardineau (Washington University, St. Louis, Missouri) in 1990, and to Charles Arntzen and Mason of BTI a year later. Arntzen and Mason were heavily involved in subsequent developments in edible vaccine technology. In 1998, Axis concluded deals with both Mycogen (San Diego, California), who own the Curtiss patents, and BTI. (Yet another approach involves using plant-derived antibodies.)

In the intervening years, the plant vaccine field had demonstrated the successful production of foreign proteins in an immunogenic state (1992), the production of antibodies in mice fed with plant material (1995), protection against disease in animals fed plant material (1997), and finally the production of antibodies in humans fed plant material (1998). The latter trials involved the ingestion of "bite-sized chunks" of delicious raw potato from a plant producing LT-B - the binding subunit of a toxin from enterotoxigenic Escherichia coli. A pentamer of LT-B binds gut epithelial cells and allows the active LT-A toxin subunit to enter the cell. The trial participants ate 50 or 100 g of raw potato on each of three occasions, for a mean of 0.75 mg of LT-B per dose. Ten of eleven showed a fourfold rise in serum antibodies, and six of eleven showed a fourfold rise in secretory (IgA) antibodies.

Potential Pitfalls

The LT-B trials directed by Arntzen are encouraging, but no one is relaxing yet. "People said edible vaccines would never work," says Cubitt. "Then when LT-B elicited a good response they said of course it works because [the bacterium and the protein are] normally in the gut. For non-enteric diseases it is not so clear. There it depends on how we present the protein."

When given orally, a particulate virus or even bacterium is efficiently sampled by the immune system. Although LT-B may be a special case, single proteins are usually not efficiently taken up. One solution that the BTI is working on is to produce complete, empty virus-like particles in plants simply by expressing the coat protein. "We've shown that we can produce these structures with Norwalk virus in plants," says Mason. "The efficiency is questionable and variable, but I think it's largely a problem with the level of expression."

Virus-like particles or not, expression levels remain a challenge. The solution may be inducible expression at a particular time, to limit toxicity to the plant.

The flip side - containing expression - is also a concern. We do not make antibodies to all of our food because of tolerance - the damping down of the immune system in the face of overwhelming amounts of antigen. The escape of a vaccine plant into the general food chain could be a disaster if it induced tolerance to a major surface protein of a virus. "One can't say at this point that it's not a possibility," says William Langridge (Loma Linda University, California). "We hope [Axis] will fund further research into this question."

Langridge stresses, however, that tolerance looks to be an unlikely prospect. His experience stems from the successful induction of tolerance to a diabetes autoantigen in mice (thus preventing further destruction of the pancreas). This was achieved with plant material, but only when the autoantigen was fused to LT-B, so that the complex entered gut epithelial cells efficiently. In earlier work an unfused autoantigen induced tolerance only after two months of continuous feeding.

The safety issue is particularly sensitive following the public uproar in Britain over genetically modified (GM) foods. This curious incident was sparked by one researcher's description of his unpublished and questionable results on a TV show. "It's bizarre what has happened in the U.K.," says Cubitt. "Science is being ignored in the formation of the public perception here." In the United States, there is an equally distressing state of affairs - complete apathy - and it is in that country that Axis grows its crops (in greenhouses). But even in Britain, Cubitt does not anticipate any problems. "We are not involved because we are in pharmaceutical products not food products - we are already highly regulated and not planning to grow large areas of crops," he says. "There may be a moratorium on growing in the field or growing agricultural products, but we grow in the U.S. and we don't do agriculture. It's nothing to do with us."

Business Basics

Vaccines used to be a treacherous business, filled with interminable trials with thousands of participants, and endless lawsuits from the few of the vaccinated millions with an adverse reaction. No more.

"The vaccine field has changed out of all recognition in the last ten years," says Cubitt. "The reason it has changed is that, if you don't use the whole organism you can't cause the disease, so you get away from the liability issues."

"It's turned from being the Cinderella of the business to being very attractive," he says. "It's now one of the most profitable parts of the pharmaceutical industry."

Protection from liability has also come from legislation, and the size of some trials has been scaled back if the protective levels of antibody are known from an earlier vaccine (as is the case with Axis's hepatitis B vaccine). Axis is further protecting itself by drawing extensively on the expertise of academic collaborators. It uses this expertise, for example, to identify the proteins or epitopes for use in vaccines.

The Promise to the Developing World

The dream of a vaccine-laden banana tree in every backyard is not going to happen - for starters, there is the containment issue. Cubitt says the final vaccine "won't be fresh material; it will be a powdered formulation that can be stored at room temperature." How the temperature stability will be achieved has not been disclosed but, he says, "we believe that our approaches will lead to temperature stability."

Could this material be produced in the countries that need it most? "The type of technology we are using is more related to food processing technology than pharmaceutical technology, because we are not taking out the food material or doing a purification," says Cubitt. "Theoretically this could be produced around the world, but we need to know that it is produced under pharmaceutical controls, not agricultural controls. These are pharmaceutical products, not agricultural products."

In the final stages of production, edible vaccines may resemble the pharmaceuticals that they most certainly are. But if the vaccines work, the wonder of their source will remain: protection from disease using only sunlight, dirt, and water as the primary ingredients.

------------------------------------------------------------------------

William A. Wells is a freelance science writer based in San Francisco.

Caleb Brown is an illustrator and biologist living in Montana. By day he drives a delivery van, and by night he draws pictures with his computer.

Edible Vaccines - an outline of principles, plus a bibliography of research papers.

DNA Vaccine Web - a rich resource of information on vaccines including new clinical updates, research articles, Web sites, and protocols.

World Health Organization: Vaccines - information on all major vaccine-preventable diseases, dealing with the disease itself, the vaccine, and research and policy for each.

Understanding Vaccines - a downloadable brochure on vaccines and the immune system. In PDF format; requires Adobe Acrobat Reader. From the National Institute of Allergy and Infectious Diseases.

Plant Biotechnology - an overview of plant biotechnology at Boyce Thompson Institute for Plant Research as it relates to new pharmaceutical products.

Living in a Genetically Modified World - a New Scientist special feature on genetically modified food.

By Sean Henahan, Access Excellence

Baltimore, MD (12/05/98)- The successful production of anti-herpes antibodies in soy plants could represent a cheap and efficient method for creating vaccines, report researchers at Johns Hopkins University.

The researchers genetically modified soybeans to produce human antibodies to herpes simplex virus two, and then compared the activity of the antibodies to those produced by the current standard, mammalian cell culture. In animal studies, the soy-produced antibodies showed similar stability in human semen and cervical mucus, as well as similar efficacy in preventing herpes infection.

Most research with monoclonal antibodies has focused on the therapeutic potential these proteins might provide against cancer and infectious disease. The current research takes a different tack, aiming to produce antibodies that might be used as a vaccine to be applied topically. So far these studies have been conducted only with mice, the scientists believe monoclonal antibodies produced by plants could work well as a cheap and efficient topical lubricant for prevention of herpes worldwide.

"Everybody wants to lower their manufacturing costs, but we're talking about several orders of magnitude of difference in thinking," said Hopkins biophysicist Kevin Whaley. "Right now, people are using the antibodies for therapeutic purposes, and it costs from $200 to $1,000 a dose. We believe we can bring the costs for preventative applications down to pennies per application. As a public health product, this will be the biggest bang for the buck."

Before human trials with the soy-produced proteins can begin, the potential vaccine will have to undergo further safety testing. Following the success with genetically modified soy, the researchers are now working on producing even more effective antibodies in corn, hoping to develop a topical lubricant that could serve to prevent sexually transmitted disease and pregnancy.

"Eventually, these microbicides may merge contraceptive technology with sexually-transmitted disease technology and create the breakthrough we're hoping for in the field of reproductive health," Whaley said. "As costs go down, there will be the move to universal precautions, just like washing your hands after you use the bathroom, brushing your teeth after you eat, and having safe sex."

The research is reported in the December 1998 issue of the journal "Nature Biotechnology."